Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 251-020-3 | CAS number: 32388-55-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
A toxicokinetic assessment was conducted in accordance with REACH Annex VIII 8.8.1. Methyl cedryl ketone (MCK) is a mono constituent organic liquid.
A full ADME toxicokinetic study in the rat is not available. In vivo studies covering the oral route in rats are available (90-day repeated dose toxicity, pre-natal developmental toxicity). A dermal 90-day repeated dose toxicity study in the rat is available. A skin sensitisation study in mice (LLNA) and an in vitro skin irritation study with human epidermis is available. No studies via the inhalation route are available. For further details on study summaries, reference is made to the appropriate sections in the IUCLID 6 registration dossier.
Based on the physicochemical properties and information in the dossier, MCK is readily absorbed via the oral route; absorption via the dermal and inhalational routes is expected to be low. MCK may accumulate on repeated exposure and alicyclic ketones are typically reduced to the corresponding secondary alcohol and excreted primarily as glucuronic acid conjugates in the urine. The alpha-2u-globulin-mediated nephropathy noted in male rats is not relevant for human health risk assessment.
The default absorption rates of 50% (oral and dermal) and 100% (inhalation) are accepted for chemical risk assessment purposes.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
- Absorption rate - oral (%):
- 50
- Absorption rate - dermal (%):
- 50
- Absorption rate - inhalation (%):
- 100
Additional information
In accordance with the ECHA Guidance on Information Requirements and Chemical Safety Assessment, Chapter R.7C Section R.7.12 (Endpoint Specific Guidance), the physicochemical properties can provide an insight into the potential behaviour of MCK in the body.
1.Physicochemical properties
Absorption - oral
The molecular weight of MCK (246 g/mol) is in the range of favourable oral absorption (<500 g/mol). The octanol/water partition coefficient (log Kow) of MCK (5.9 at 30°C) indicates it is highly lipophilic. Based on the chemical structure, MCK has no groups which will dissociate in a relevant pH range (2-10) so is likely to be present in a non-ionised form. The molecular weight of MCK is indicative of absorption after oral administration. This might occur by micellular solubilisation, due to the high log Kow and poor water solubility (6 mg/L at 23°C).
Absorption – dermal
The physical state of MCK, low vapour pressure (0.25kPa at 25°C; boiling point 320.9°C) and the molecular weight (246 g/mol) indicates that dermal absorption is possible. The water solubility (6 mg/L at 23°C) indicates low to moderate absorption while the high log Kow (5.9 at 30°C) is an indication for a high uptake into the stratum corneum, but a limited rate of penetration into the lower layers of the epidermis and dermis. In the final decision (CCH-D-2114453248-46-01), ECHA indicate “the water solubility and Log Kow of the registered substance are reported to be 6 mg/L and 5.9 respectively therefore suggesting low absorption through the skin into the systemic circulation”.
Absorption – inhalation
Due to the low vapour pressure of MCK (0.25kPa at 25°C; boiling point 320.9°C) respiratory exposure is expected to be low. However, some respiratory exposure may occur as MCK is used as a fragrance ingredient. The low water solubility (6 mg/L at 23°C) and high lipophilicity may enhance penetration in the lower respiratory tract.
Distribution/Metabolism/Excretion
Typically, lipid-soluble substances may reach all compartments and accumulate in fat. Based on the molecular weight and high lipophilicity, MCK will most likely distribute into tissues. Based on the chemical structure, there are no hydrolysable functional groups present, so in order to facilitate excretion, the highly lipophilic parent substance is likely to be converted to polar metabolites for excretion.
2. Information from other studies in the dossier
An in vitro human skin permeation study and milk transfer study in rats did not meet data quality requirements and were not included in the dossier.
Absorption (oral)
In a 90-day repeated dose toxicity study, MCK was administered to Wistar Crl:WI(Han) rats (10/sex/dose) by gavage in corn oil at dose levels of 0, 25, 80 and 250 mg/kg bw/day daily (OECD 408/GLP). On histopathological analysis, there were induced findings in the liver, thyroid and kidney in males and females at 250 mg/kg bw/day. The effects in liver and thyroid were considered adaptive and/or confined to groups dosed at 250 mg/kg bw/day. The effects in the kidney were related to alpha2u-globulin nephropathy in male rats and not relevant for humans. The NOAEL (male/female) was 80 mg/kg bw/day.
In a pre-natal developmental toxicity study (equivalent or similar to OECD 414/GLP), MCK was administered to 25 Sprague Dawley; Crl:CD (SD) IGS BR VAF/Plus females by gavage in corn oil at dose levels of 0, 25, 50, or 100 mg/kg bw/day from days 7 through 17 of gestation. Some effects were noted e.g. clinical signs, food consumption, reduction body weight gains from GD 7-10, in maternal animals only. The NOAEL (maternal) was 100 mg/kg bw/day; the NOAEL (developmental) was 50 mg/kg bw/day.
Based on these studies, the substance is readily absorbed via the oral route. For chemical safety assessment purposes, based on the physicochemical properties and information in the dossier, a default oral absorption of 50% is accepted.
Absorption (dermal)
In a 90-day repeated dose toxicity study (OECD 411/GLP), MCK was applied to the shaved skin of four groups of Crl:CD(SD)IGS BR male and female rats (15/sex/group) at dose levels of 0, 50, 150, 300 mg/kg bw/day, 6 -7 hours/day for 7 days/week during a 13 week period, with a 4 week recovery period. There were no effects noted except pathology in the male kidneys (indicator of the male alpha2u-globulin nephropathy noted in the oral study above) and dermal irritation; the latter effects were dose dependent but were resolved upon sacrifice or were almost fully resolved during weeks 14 -15 of the recovery phase. The NOAEL (male/female) was 300 mg/kg bw/day. The data from this study indicates that extended lower dose exposure may cause local dermal irritation, which could increase absorption. However, the in vitro skin irritation study using human epidermis tissue indicated that MCK is a non-irritant; human skin is typically less permeable than rabbit/rat skin. A skin sensitisation study in the mouse indicated that MCK is classified for skin sensitisation (Category 1B), so despite the high log Kow, which may limit systemic exposure, some dermal uptake occurs. In their draft decision (CCH-D-2114435755-43-01), ECHA concluded that “the sensitising property of the registered substance leads to the corresponding adverse effects seen on the skin of the test animals”, in reference to the effects noted in the repeated dose dermal toxicity study.
The ECHA guidance criteria (Chapter R.7C) state that 10% dermal absorption is used when the molecular weight of the substance is >500 and the log Kow is <-1 or >4, otherwise 100% dermal absorption is used. In general, dermal absorption will not be higher than oral absorption, so for chemical safety assessment purposes a dermal absorption rate of 50% is accepted.
Absorption (inhalation)
There are no inhalation studies available for the substance. For chemical safety assessment, based on the physicochemical properties, the default inhalation absorption rate of 100% is accepted.
Distribution/Metabolism/Excretion
Based on the dermal irritation noted in the repeated dose dermal toxicity study, MCK may persist in the stratum corneum, due to its high lipophilicity; it may accumulate upon repeated oral exposure also, based on the liver effects noted in the 90-day oral toxicity study. In the final decision (CCH-D-2114453248-46-01), it was stated that “ECHA accordingly considers that the kidney is a target organ of the registered substance”. However, as the sub-chronic oral and dermal studies indicate, these effects were only observed in male rats and indicate that the substance induces alpha-2u-globulin-mediated nephropathy, which is not relevant for human health risk assessment. There is no direct evidence to indicate the metabolic pathway or route of excretion of the substance; alicyclic ketones are typically reduced to the corresponding secondary alcohol and excreted primarily as glucuronic acid conjugates in the urine (WHO, 2003). The liver effects noted in males at 250 mg/kg bw/day may indicate an overloading of the metabolic pathway, so the liver could become a depot for insufficiently metabolised substance.
Safety evaluation of certain food additives / prepared by the fifty-ninth meeting of the Joint FAO/WHO Expert Committee on Food Additives, 2003. (WHO food additives series 50)
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.